Petition to the FDA to Require a Black-Box Warning for Commonly Used Type 2 Diabetes Drugs Known as SGLT2 Inhibitors

View as PDF

View press release

Public Citizen petitioned the Food and Drug Administration (FDA) to add a black-box warning to the product labeling for the commonly used Type 2 diabetes drugs known as SGLT2 inhibitors, as they can lead to potentially fatal diabetic ketoacidosis in Type 1 diabetes patients for whom the drugs are not approved.

June 24, 2020, FDA acknowledgment letter.